PMID: 40380Aug 1, 1979

Comparative potency and speed of onset of fazadinium and d-tubocurarine

Acta Anaesthesiologica Scandinavica
S Z HussainA T Birmingham

Abstract

The potency and speed of onset of fazadinium and d-tubocurarine have been compared at three cumulative doses. Wtih thiopentone as the induction agent, the dose ratio fazadinium/d-tubocurarine ranged from 1.2 to 1.3 for single twitch reduction and from 1.1 to 1.2 for reduction of tetanus. The times taken for the development of 50% and 100% effect after each dose increment were not significantly different for the three doses of fazadinium and the 2nd and 3nd doses of d-tubocurarine. However, the 1st dose of d-tubocurarine was markedly slower than fazadinium to achieve a 50% and 100% effect.

References

Feb 1, 1993·Acta Anaesthesiologica Scandinavica·S P Roberts, B J Pollard
Mar 1, 1984·Environmental Health Perspectives·O Andersen

Citations

Jan 1, 1976·Canadian Anaesthetists' Society Journal·R HughesN Sugai
Apr 1, 1978·British Journal of Anaesthesia·C L Blackburn, M Morgan
Apr 1, 1971·British Journal of Anaesthesia·J StovnerE Bjelke
May 1, 1973·Anaesthesia·A J ColemanW P Leary
Sep 1, 1968·Anesthesiology·L F WaltsJ B Dillon

Related Concepts

Adjuvants, Anesthesia
Intravenous Injections
Fazadinium
Inotropism
Tetanus
Muscle Twitch
Thiopental
Tubocurarine Chloride
Tubocurarine
Nerve-Muscle Preparation

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Synapse Loss as Therapeutic Target in MS

As we age, the number of synapses present in the human brain starts to decline, but in neurodegenerative diseases this occurs at an accelerated rate. In MS, it has been shown that there is a reduction in synaptic density, which presents a potential target for treatment. Here is the latest research on synapse loss as a therapeutic target in MS.

Artificial Intelligence in Cardiac Imaging

Artificial intelligence (ai) techniques are increasingly applied to cardiovascular (cv) medicine in cardiac imaging analysis. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

Social Learning

Social learning involves learning new behaviors through observation, imitation and modeling. Follow this feed to stay up to date on the latest research.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Single Cell Chromatin Profiling

Techniques like ATAC-seq and CUT&Tag have the potential to allow single cell profiling of chromatin accessibility, histones, and TFs. This will provide novel insight into cellular heterogeneity and cell states. Discover the latest research on single cell chromatin profiling here.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells.